EIF3B promotes cancer progression in pancreatic cancer
BACKGROUND: This study aimed to analyze the relative expression of Eukaryotic Translation Initiation Factor 3 Subunit B (EIF3B) in pancreatic cancer and elucidate its contribution to this disease.
METHODS: Relative expression of EIF3B in pancreatic cancer was analyzed by immunohistochemistry. Cell viability was determined by the MTT assay and cell proliferation was measured by direct cell counting. Cell apoptosis was detected by Annexin V staining followed by flow cytometry analysis, and cell cycle was analyzed by PI staining. The differential expression gene analysis was performed by microarray. Tumor progression in response to EIF3B deficiency in vivo was investigated using the xenograft tumor model.
RESULTS: We found aberrantly high expression of EIF3B in pancreatic cancer, which associated with unfavorable prognosis. Knockdown of EIF3B greatly compromised cell viability and proliferation in both SW1990 and PANC-1 cells. Furthermore, EIF3B deficiency induced cell cycle arrest and spontaneous apoptosis. In vivo tumor progression was significantly suppressed by EIF3B silencing in the xenograft mouse model. Mechanistically, we characterized down-regulation of CDH1 and IRS1 and up-regulation of DDIT3, PTEN and CDKN1B, in response to EIF3B knockdown, which might mediate the oncogenic effect of EIF3B in pancreatic cancer.
CONCLUSIONS: Our data uncovered the oncogenic role of EIF3B in pancreatic cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Scandinavian journal of gastroenterology - 56(2021), 3 vom: 05. März, Seite 281-288 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Hanzhang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apoptosis |
|---|
| Anmerkungen: |
Date Completed 18.08.2021 Date Revised 21.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/00365521.2020.1868566 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320216799 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320216799 | ||
| 003 | DE-627 | ||
| 005 | 20231225173114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00365521.2020.1868566 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320216799 | ||
| 035 | |a (NLM)33459066 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Hanzhang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a EIF3B promotes cancer progression in pancreatic cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2021 | ||
| 500 | |a Date Revised 21.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: This study aimed to analyze the relative expression of Eukaryotic Translation Initiation Factor 3 Subunit B (EIF3B) in pancreatic cancer and elucidate its contribution to this disease | ||
| 520 | |a METHODS: Relative expression of EIF3B in pancreatic cancer was analyzed by immunohistochemistry. Cell viability was determined by the MTT assay and cell proliferation was measured by direct cell counting. Cell apoptosis was detected by Annexin V staining followed by flow cytometry analysis, and cell cycle was analyzed by PI staining. The differential expression gene analysis was performed by microarray. Tumor progression in response to EIF3B deficiency in vivo was investigated using the xenograft tumor model | ||
| 520 | |a RESULTS: We found aberrantly high expression of EIF3B in pancreatic cancer, which associated with unfavorable prognosis. Knockdown of EIF3B greatly compromised cell viability and proliferation in both SW1990 and PANC-1 cells. Furthermore, EIF3B deficiency induced cell cycle arrest and spontaneous apoptosis. In vivo tumor progression was significantly suppressed by EIF3B silencing in the xenograft mouse model. Mechanistically, we characterized down-regulation of CDH1 and IRS1 and up-regulation of DDIT3, PTEN and CDKN1B, in response to EIF3B knockdown, which might mediate the oncogenic effect of EIF3B in pancreatic cancer | ||
| 520 | |a CONCLUSIONS: Our data uncovered the oncogenic role of EIF3B in pancreatic cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a EIF3B | |
| 650 | 4 | |a apoptosis | |
| 650 | 4 | |a cell cycle | |
| 650 | 4 | |a cell viability | |
| 650 | 4 | |a pancreatic cancer | |
| 650 | 7 | |a EIF3B protein, human |2 NLM | |
| 650 | 7 | |a Eukaryotic Initiation Factor-3 |2 NLM | |
| 700 | 1 | |a Shan, Yuqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Wencheng |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Changku |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scandinavian journal of gastroenterology |d 1966 |g 56(2021), 3 vom: 05. März, Seite 281-288 |w (DE-627)NLM000055166 |x 1502-7708 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2021 |g number:3 |g day:05 |g month:03 |g pages:281-288 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/00365521.2020.1868566 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2021 |e 3 |b 05 |c 03 |h 281-288 | ||